Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalmefene Autoinjector vs Narcan for Fentanyl-Induced Respiratory Depression
NCT06719986Phase 1Completed
- Sponsor
- Purdue Pharma
- Start
- Oct 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nalmefene in opioid overdose (2 arms), sponsored by Purdue Pharma. Primary endpoint: Change in Minute Ventilation 5 Minutes From Opioid Induced Nadir at 5 months. Started Oct 2022; status: completed.
02
Drugs
nalmefene
03
Conditions
opioid overdose
Beyond the preview
Go deeper on NCT06719986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06719986.